Therapeutic potential of the IL-3-IL-5-GM-CSF common beta receptor to treat upper and lower allergic airway

IL-3-IL-5-GM-CSF 共同 β 受体治疗上、下过敏性气道的治疗潜力

• 批准号: nhmrc : 510803
• 负责人: Dr Kelly Asquith
• 金额: $ 10.03万
• 依托单位: The University of Newcastle
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-01-01 至 2012-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/therapeutic-potential-il-allergic-airway/115579
• 关键词: Therapeutic; potential; IL; GM; CSF

This research aims to develop new treatments for allergic diseases such as asthma and allergic rhinitis, which remain significant public health problems in Australia. We will develop new therapies with the potential to completely suppress acute and chronic allergic disease targeting a common receptor protein that controls multiple facets of allergic inflammation. We will test antibodies intended to treat human asthma using a novel mouse strain expressing the human form of this receptor.

这项研究旨在为过敏性疾病如哮喘和过敏性鼻炎开发新的治疗方法，这些疾病在澳大利亚仍然是重大的公共卫生问题。我们将开发新的疗法，有可能完全抑制急性和慢性过敏性疾病，靶向控制过敏性炎症多个方面的共同受体蛋白。我们将使用表达这种受体的人类形式的新型小鼠品系来测试用于治疗人类哮喘的抗体。